Key Takeaways Zoetis is set to report Q3 2025 results, with revenue and EPS estimates at $2.41B and$1.62, respectively.Companion animal drugs like Simparica Trio, Apoquel, and Cytopoint likely boosted quarterly sales.Livestock product revenue may have fallen due to the divestiture of feed additives and water-soluble assets.Zoetis, Inc. (ZTS) is expected to beat expectations when it reports its third-quarter 2025 earnings on Nov. 4, 2025, before the opening bell.The Zacks Consensus Estimate for the to-be-re ...